This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Challenge to Medtronic Ireland renal denervation patent reinstated in US

By Melissa Ritti ( March 27, 2025, 20:21 GMT | Insight) -- ReCor Medical and Otsuka Medical Devices saw their challenge to renal neuromodulation technology owned by Medtronic Ireland reinstated today by the US Court of Appeal for the Federal Circuit, which agreed that the Patent Trial and Appeal Board failed to consider “everything” taught by a prior art catheter with ultrasonic transducer. That the earlier-filed, and since-expired, patent chronicles use on pulmonary veins was no reason for it to be disregarded, the appeals court said.The US Patent and Trademark Office’s Patent Trial and Appeal Board must take another look at a Medtronic Ireland patent utilized in a new treatment of hypertension which only recently gained regulatory approval, a federal appeals court said....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections